Japan Approves Astellas Transplant Drug Delayed In U.S.
This article was originally published in PharmAsia News
Executive SummaryAstellas Pharma said it has won approval to market its Graceptor (tacrolimus) transplant drug in Japan. The new version is a once-daily form of Astellas' twice-daily Prograf, a $2 billion-a-year seller for the company, but one that lost its U.S. patent protection earlier this year. The U.S. FDA has yet to approve tacrolimus as a treatment for kidney and liver transplants, issuing "approvable" letters on the grounds Astellas submitted insufficient data. The U.S. agency also has declined approval for a heart transplant indication, issuing a "non approvable" letter. Tacrolimus already is approved in Europe, where it is marketed as Advagraf. (Click here for more
You may also be interested in...
ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.
Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac
Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.
In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.